The Unique Value of Detecting Preeclampsia: Comparing Health Economic Analyses of Novel Diagnostics With the ISPOR Value Flower
Author(s)
Ryan Callahan1, Gareth Obery, MSc, MD2.
1Prova Health, Granger, IN, USA, 2Prova Health, London, United Kingdom.
1Prova Health, Granger, IN, USA, 2Prova Health, London, United Kingdom.
OBJECTIVES: Pre-eclampsia is a significant cause of fetal and maternal morbidity and mortality. Novel diagnostics to detect pre-eclampsia early in pregnancy offer substantial clinical and economic benefits and have been approved in several worldwide markets. Health economic evaluations of these technologies (e.g., sFlt-1/PlGF ratio tests) face methodological constraints and as a result may have incompletely analyzed their value, prioritizing certain measurements of cost savings without building more comprehensive value narratives. This pattern of evidence development contributes to uneven adoption of novel diagnostics, despite the significant long-term health and societal burden of pre-eclampsia.
METHODS: We performed a narrative review of health economic literature on related technologies, categorizing each according to primary endpoints and results. We then reviewed clinical guidelines and other literature on technologies in development and on the market to characterize potential benefits, particularly through the lens of the ISPOR Value Flower methodology, which considers core, common, and novel broader value elements.
RESULTS: The study provides the first known holistic evaluation of these technologies using the ISPOR Value Flower methodology. We demonstrate that significant drivers of value to pregnant women and society have been underdiscussed, including “real option value” for younger patients, the "value of knowing" (reduced anxiety, informed decision-making), "insurance value" (protection against severe, unpredictable complications), and "severity of disease" (mitigation of stillbirth and long-term maternal sequelae). We further demonstrate how for pre-eclampsia in particular, additional benefits are likely to accrue at a population level from the reduction in use of demographic-based risk stratification methods.
CONCLUSIONS: As these technologies continue to mature in the age of -omics, health economic evaluations should consider diverse drivers of value, such as the profound impact on patient quality of life, long-term health outcomes, and broader societal benefits, to support consistent and equitable adoption.
METHODS: We performed a narrative review of health economic literature on related technologies, categorizing each according to primary endpoints and results. We then reviewed clinical guidelines and other literature on technologies in development and on the market to characterize potential benefits, particularly through the lens of the ISPOR Value Flower methodology, which considers core, common, and novel broader value elements.
RESULTS: The study provides the first known holistic evaluation of these technologies using the ISPOR Value Flower methodology. We demonstrate that significant drivers of value to pregnant women and society have been underdiscussed, including “real option value” for younger patients, the "value of knowing" (reduced anxiety, informed decision-making), "insurance value" (protection against severe, unpredictable complications), and "severity of disease" (mitigation of stillbirth and long-term maternal sequelae). We further demonstrate how for pre-eclampsia in particular, additional benefits are likely to accrue at a population level from the reduction in use of demographic-based risk stratification methods.
CONCLUSIONS: As these technologies continue to mature in the age of -omics, health economic evaluations should consider diverse drivers of value, such as the profound impact on patient quality of life, long-term health outcomes, and broader societal benefits, to support consistent and equitable adoption.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
MT42
Topic
Economic Evaluation, Medical Technologies, Study Approaches
Disease
Reproductive & Sexual Health, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)